Location History:
- Princeton Junction, NJ (US) (2005 - 2016)
- Pennington, NJ (US) (2019)
- West Windsor, NJ (US) (2017 - 2024)
Company Filing History:
Years Active: 2005-2024
Title: Innovations of Han Chang in Cancer Treatment
Introduction: Han Chang, based in Princeton Junction, NJ, is a prolific inventor in the field of cancer research, holding 27 patents to date. His work primarily focuses on advanced therapies for cancer treatment, particularly small cell lung cancer (SCLC). His innovative methods and treatments aim to improve patient outcomes and provide new avenues for battling this aggressive disease.
Latest Patents: Among Han Chang's notable patents are innovative methods for treating tumors derived from small cell lung cancer, specifically targeting patients with high tumor mutational burden (TMB) status. One patent details a unique approach involving monotherapy with an anti-PD-1 antibody or a combination therapy that includes an anti-CTLA-4 antibody. This method not only specifies the treatment regimen but also underscores the importance of identifying suitable candidates for therapy by measuring their TMB status through nucleic acid sequencing. Additionally, he has developed patents for antibodies that bind to OX-40, indicating potential therapeutic uses in cancer treatment.
Career Highlights: Han Chang contributes his expertise to Bristol Myers Squibb Company, where he leverages his patent portfolio to drive forward the company's mission in developing innovative cancer therapies. His commitment to research and development has led to significant advancements in immunotherapy, positioning him as a key player in the pharmaceutical industry.
Collaborations: Throughout his career, Han has collaborated with esteemed colleagues, including Glen Eugene Mikesell and Robert Peach. These partnerships have facilitated groundbreaking research and the development of therapies that have the potential to transform cancer treatment paradigms.
Conclusion: Han Chang's contributions to the field of cancer therapy are marked by his extensive patent portfolio and his innovative approaches to treatment. As he continues his work at Bristol Myers Squibb, his inventions will likely pave the way for new, effective therapies for patients battling cancer, particularly those suffering from small cell lung cancer.